← signals
2026-07-22·ANTHROPIC·market cap prediction
lowup

Multiple Manifold Markets prediction questions indicate growing market confidence in Anthropic's future valuation...

Multiple Manifold Markets prediction questions indicate growing market confidence in Anthropic's future valuation relative to its main competitor, OpenAI.

window 60devidence 5confidence score 91

confidence score

Strong evidence: 1 independent source class support this read.

91
low confidence1 independent source classesmarketpasses publish gate

signal brief

Multiple Manifold Markets prediction questions indicate growing market confidence in Anthropic's future valuation relative to its main competitor, OpenAI. The most notable signal is a 69.37% probability that Anthropic will have a higher market capitalization than OpenAI after both companies go public (Source 4). This is a strong, albeit speculative, indicator of shifting competitive sentiment. Additionally, there is a 39.67% chance that Anthropic or OpenAI will introduce a higher-tier subscription costing $400 or more in 2026 (Source 3), suggesting potential pricing power and revenue expansion. Other questions show lower probabilities: only 3.46% that any of OpenAI, Anthropic, or Databricks will IPO with a market cap over $200B by August 2026 (Source 5), implying near-term IPO valuations are seen as modest. The risk of nationalization is deemed low at 16.48% (Source 1). While all data comes from prediction markets and not confirmed events, the aggregate tilt toward Anthropic outpacing OpenAI in eventual market cap is a notable shift in perceived competitive dynamics.

What the sources said:

  • Source 4: "Will Anthropic have a higher market cap than OpenAI after both IPO? YES=69.37%" Manifold Markets
  • Source 3: "Will Anthropic or OpenAI add a higher tier subscription >= 400$ in 2026? YES=39.67%" Manifold Markets
  • Source 5: "Will any of OpenAI, Anthropic, or Databricks go public with a market cap over $200B by August 15, 2026? YES=3.46%" Manifold Markets

source data used

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.